Kevin Kalinsky, MD, MS

Kevin Kalinsky, MD, MS, is a professor and director of the Division of Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and the Louisa and Rand Glenn Family Chair in Breast Cancer Research and director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Articles

Mechanisms of Action of Antibody-Drug Conjugates

September 29th 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

Overview of Antibody-Drug Conjugates (ADCs)

September 29th 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

May 29th 2023

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

May 22nd 2023

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.

HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

May 22nd 2023

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

May 15th 2023

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.

Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

May 15th 2023

Expert oncologist Kevin Kalinsky, MD, MS, reviews a patient case of HER2+ metastatic breast cancer and highlights key findings in this disease setting.

Dr Kalinsky on Differences in Efficacy Between CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

May 1st 2023

Kevin Kalinsky, MD, MS, discusses differences in efficacy data for CDK4/6 inhibitors in the treatment of patients with metastatic hormone receptor–positive/HER2-negative breast cancer.

Dr. Kalinsky on the Importance of Molecular Profiling in Breast Cancer

October 25th 2022

Kevin Kalinsky, MD, MS, discusses the importance of molecular profiling in breast cancer.

Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast Cancer

July 14th 2022

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

May 4th 2022

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Dr. Kalinsky on Strategies to Prevent Recurrence in Early Breast Cancer

April 26th 2022

Kevin Kalinsky, MD, MS, discusses the potential benefits of chemotherapy in preventing disease recurrence in premenopausal patients with breast cancer.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

February 3rd 2022

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.

ADC Therapies in Development in Breast Cancer

February 3rd 2022

An overview of novel antibody-drug conjugate therapies currently under investigation as presented at SABCS 2021.

SABCS 2021 Updates in ER+ Breast Cancer

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Sacituzumab Govitecan Safety Profile in TNBC

January 28th 2022

Strategies that can be used to mitigate and manage adverse events associated with sacituzumab govitecan therapy for triple-negative breast cancer.

Sacituzumab Govitecan for TNBC

January 28th 2022

Komal Jhaveri, MD, FACP, provides rationale for treating a patient with triple-negative breast cancer with sacituzumab govitecan.

Managing Patients With MBC on T-DXd Therapy

January 21st 2022

Strategies used to help monitor and manage T-DXd treatment-related adverse events.